Non–Small Cell Lung Cancer, Version 4.2024

Gregory J. Riely, Douglas E. Wood, David S. Ettinger, Dara L. Aisner, Wallace Akerley, Jessica R. Bauman, Ankit Bharat, Debora S. Bruno, Joe Y. Chang, Lucian R. Chirieac, Malcolm DeCamp, Aakash P. Desai, Thomas J. Dilling, Jonathan Dowell, Gregory A. Durm, Scott Gettinger, Travis E. Grotz, Matthew A. Gubens, Aditya Juloori, Rudy P. LacknerMichael Lanuti, Jules Lin, Billy W. Loo, Christine M. Lovly, Fabien Maldonado, Erminia Massarelli, Daniel Morgensztern, Trey C. Mullikin, Thomas Ng, Dawn Owen, Dwight H. Owen, Sandip P. Patel, Tejas Patil, Patricio M. Polanco, Jonathan Riess, Theresa A. Shapiro, Aditi P. Singh, James Stevenson, Alda Tam, Tawee Tanvetyanon, Jane Yanagawa, Stephen C. Yang, Edwin Yau, Kristina M. Gregory, Lisa Hang

Research output: Contribution to journalArticlepeer-review

Abstract

The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Non–Small Cell Lung Cancer (NSCLC) provide recommendations for the treatment of patients with NSCLC, including diagnosis, primary disease management, surveillance for relapse, and subsequent treatment. The panel has updated the list of recommended targeted therapies based on recent FDA approvals and clinical data. This selection from the NCCN Guidelines for NSCLC focuses on treatment recommendations for advanced or metastatic NSCLC with actionable molecular biomarkers.

Original languageEnglish
Pages (from-to)249-274
Number of pages26
JournalJournal of the National Comprehensive Cancer Network : JNCCN
Volume22
Issue number4
DOIs
StatePublished - May 2024

Keywords

  • Biomarkers, Tumor/genetics
  • Carcinoma, Non-Small-Cell Lung/therapy
  • Humans
  • Lung Neoplasms/diagnosis
  • Molecular Targeted Therapy/methods
  • Neoplasm Staging

Fingerprint

Dive into the research topics of 'Non–Small Cell Lung Cancer, Version 4.2024'. Together they form a unique fingerprint.

Cite this